Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cintas Corporation (CTAS) vs Viatris Inc (VTRS) Price & Performance

Cintas CorporationTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Cintas Corporation vs Viatris Inc — how do they compare? Cintas Corporation trades at $204.5 (market cap $82.15B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Cintas Corporation is far larger — about 4.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.

CTASVTRS
Market Cap
$82.15B$18.69B
Sector
IndustrialsHealth
52-Week High
$225.10$17.86
52-Week Low
$163.55$9.49
Enterprise Value
$84.56B$30.80B
Dividend Yield
1.01%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cintas Corporation

No Aura AI signal available yet.

Viatris Inc

Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.

Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.

Returns comparison

Trailing returns across standard periods

About Cintas Corporation

In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).

Read more on CTAS

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS